JNJ Jun 2023 120.000 put
| Previous Close | 0.2500 |
| Open | 0.2500 |
| Bid | 0.1000 |
| Ask | 0.3200 |
| Strike | 120.00 |
| Expire Date | 2023-06-16 |
| Day's Range | 0.2500 - 0.2500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 669 |
- Motley Fool
3 Low-Risk Dividend Stocks to Buy in 2023
These stocks should allow you to sleep peacefully no matter what happens with the stock market this year.
- Motley Fool
2 of the Best Dividend Stocks to Own in 2023
In either case, it's a good idea to add some dividend stocks to your portfolio. If you want to benefit from passive income and potential growth, I've got two stocks in mind. The stocks I'm talking about also have reached a turning point that could lead to earnings growth down the road.
- Reuters
UPDATE 1-J&J says blood cancer drug improves progression-free survival in patients
Johnson & Johnson said on Friday an interim analysis showed its drug Carvykti met the main goal of improving progression-free survival in patients with a type of blood cancer in a late-stage study. The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies. Carvykti, developed by J&J and its China-focused partner Legend Biotech Corp, was approved by the U.S. health regulator last year based on an early-to mid-stage study to treat relapsed or refractory multiple myeloma patients who had received four or more prior lines of therapy.
